Updated:
Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance was established in 2000 with an initial $750 million pledge from the Bill & Melinda Gates Foundation. The partnership structure...
Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance was established in 2000 with an initial $750 million pledge from the Bill & Melinda Gates Foundation. The partnership structure places permanent board seats with WHO, UNICEF and the World Bank. Its mandate centers on vaccine access for children in the lowest-income countries. The organization commits resources across vaccine procurement, cold-chain infrastructure and digital delivery systems. Confirmed positions include Zipline for drone transport in Nigeria and Simprints for biometric identification in immunization tracking. Capital also supports StaTwig blockchain pilots in India and Nexleaf Analytics IoT sensors in the United States. Geographic reach spans sub-Saharan Africa, South Asia and Latin America through both direct programs and the INFUSE Pacesetter Program. Staff totals 201 across the Geneva headquarters and the Washington DC secretariat. Adjacent vehicles include the International Finance Facility for Immunisation, which has transferred more than $6.2 billion via vaccine bonds managed by the World Bank. June 2024: Gavi sponsored the Global Forum for Vaccine Sovereignty and Innovation in Paris to launch the African Vaccine Manufacturing Accelerator. The public-private board and treasury arrangement with the World Bank creates a distinct capital-raising channel unavailable to standard foundations. Sovereign pledges are securitized through IFFIm, allowing front-loaded disbursements without annual appropriation cycles.
General information
Firm type
Endowment / Foundation
Year founded
2000
Location
Region
Europe
Country
Switzerland
City
Geneva
Corporate office
Chemin du Pommier 40, 1218 Le Grand-Saconnex, Geneva, Switzerland
Additional offices
Washington, DC, United States
Principals
Dr. Sania Nishtar
CEO
Helen Clark
Board Chair
Sector focus
Frequently asked questions
Who runs investment decisions at Gavi?
Dr. Sania Nishtar serves as CEO with oversight from the board chaired by Helen Clark. Capital allocation decisions route through program teams and the INFUSE facility rather than a traditional CIO structure.
How does Gavi source proprietary deal flow?
Sourcing occurs through the INFUSE Pacesetter Program and partnerships with 500 Global. Technology providers such as Zipline and Simprints entered via this channel.
Does Gavi participate in fund commitments or only direct deals?
Activity centers on direct program funding and co-investments in operating companies. No traditional fund-of-funds commitments appear in the record.
What investment stages does Gavi typically target?
The focus remains on late-stage deployment and scaling of proven technologies rather than seed or early venture. Portfolio companies already operate in multiple countries.
Where does the underlying capital come from?
Primary sources are sovereign pledges and grants from the Bill & Melinda Gates Foundation. IFFIm converts multi-year pledges into immediate bond proceeds.
Does Gavi maintain philanthropic structures, and how are they separated?
The core entity operates as the Vaccine Alliance with IFFIm as a separate UK-registered financing vehicle. Governance documents keep program execution distinct from bond issuance.
What is Gavi's known posture on co-investments alongside external GPs?
Co-investment occurs through the Innovation Scale-Up Facility with partners such as 500 Global. The structure targets $300 million in mobilized capital for health technology.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: